Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) – a new perspective-Reference-Cited by-同舟云学术

Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) – a new perspective

Published:2021-06-21 Issue:12 Volume:62 Page:3039-3042
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Mirgh Sumeet¹^ORCID,Sharma Archana²,Folbs Bhaarat²,Khushoo Vishvdeep²,Kapoor Jyotsna²,Tejwani Narender²,Ahmed Rayaz²,Agrawal Narendra²,Choudhary Partha S.³,Mehta Pallavi²,Bhurani Dinesh²

Affiliation:

1. Adult Hematolymphoid and BMT unit, Tata Memorial Centre, ACTREC (Advanced Centre for Treatment, Research, and Education in Cancer), Navi Mumbai, India (Present Affiliation); Homi Bhabha National Institute, Mumbai, India (Present Affiliation); Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

2. Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

3. Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1941938

Reference16 articles.

1. Novel markers of normal and neoplastic human plasmacytoid dendritic cells

2. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy

3. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

4. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment;Frontiers in Medicine;2024-07-17

2. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123;Leukemia Research;2024-04

3. Plasmacytoid dendritic cell neoplasms;Blood Research;2023-04-30

4. Clinical features, immune profile and induction chemotherapy options for blastic plasmacytoid dendritic cell neoplasm: a systematic review and meta-analysis;Future Oncology;2023-03

5. Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?;Cancers;2022-08-02